AMENDMENT NO. 3 TO MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENTMutual Confidential Disclosure Agreement • January 18th, 2024 • Merck Sharp & Dohme LLC • Pharmaceutical preparations
This Amendment No. 3 to Mutual Confidential Disclosure Agreement (this “Amendment No. 3”), effective as of the date of last signature below (the “Amendment No. 3 Effective Date”), confirms the mutual understanding between Merck Sharp & Dohme LLC, having a place of business at 126 East Lincoln Avenue, Rahway, New Jersey 07065, USA (“Merck”) and Harpoon Therapeutics, Inc., having a place of business at 611 Gateway Boulevard, Suite 400, South San Francisco, California 94080, USA (“Harpoon”).
FIRST AMENDMENT TO MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENTMutual Confidential Disclosure Agreement • January 18th, 2024 • Merck Sharp & Dohme LLC • Pharmaceutical preparations
This First Amendment to the Mutual Confidential Disclosure Agreement (this “First Amendment”) is entered into as of the date of last signature below (the “First Amendment Effective Date”), by and between Merck Sharp & Dohme Corp., (“Merck”) and Harpoon Therapeutics (“Harpoon”) and amends that certain Mutual Confidential Disclosure Agreement between Merck and Harpoon, effective as of January 9th, 2020 (the “Agreement”; capitalized terms used herein without definition herein shall have the meaning given such terms in the Agreement).
Joint Filing AgreementJoint Filing Agreement • January 18th, 2024 • Merck Sharp & Dohme LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of Harpoon Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of the date set forth below.
AMENDMENT No. 2 TO MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENTMutual Confidential Disclosure Agreement • January 18th, 2024 • Merck Sharp & Dohme LLC • Pharmaceutical preparations
This Amendment No. 2 to Mutual Confidential Disclosure Agreement (“Amendment No. 2”), effective as of the date of last signature below (“Amendment No. 2 Effective Date”), confirms the mutual understanding between Merck Sharp & Dohme, LLC, having a place of business at 126 East Lincoln Avenue, Rahway, New Jersey 07065, USA (“Merck”) and Harpoon Therapeutics, having a place of business at 611 Gateway Blvd, Suite 400, South San Francisco, CA 94080 (“Harpoon”).
MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENTMutual Confidential Disclosure Agreement • January 18th, 2024 • Merck Sharp & Dohme LLC • Pharmaceutical preparations
This Mutual Confidential Disclosure Agreement (this “Agreement”), effective as of the date of last signature below (the “Effective Date”), is entered into by and between Merck Sharp & Dohme Corp., having an address of 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (hereinafter referred to as “Merck”) and Harpoon Therapeutics, having an address of 131 Oyster Point Blvd, Suite 300, South San Francisco, CA 94080 (hereinafter referred to as “Harpoon”) (each a “Party” and collectively, the “Parties”) and sets forth the terms and conditions under which the Parties will exchange certain proprietary and confidential information/data with respect to a possible business relationship around Harpoon’s pipeline programs, including but not limited to HPN424, and/or TriTAC® platform and related technologies (hereinafter collectively referred to as “Subject Matter”).
